GLP-1 weight-loss drug users spent 9.9% more on apparel after six-to-eight months on medication, according to PwC research, as body-shape changes force consumers to rework wardrobes faster than seasonal cycles anticipate.

The data, drawn from US and UK surveys of patients on drugs including Ozempic, Wegovy and Mounjaro, points to measurable shifts in clothing spend, sizing confidence and channel choice that sourcing, merchandising and supply-chain teams will need to factor into next-season orders.

What is GLP-1 usage doing to clothing spend?

Among US GLP-1 users surveyed by PwC, 73% reported a meaningful change in clothing size. The 9.9% uplift in apparel spending over the six-to-eight-month window adds an unusual growth vector to a category that has spent two years hunting incremental sales.

UK demand trails but already matters. PwC estimates that around three million British adults currently use GLP-1 medications, with 40% of UK respondents saying they spend more on clothing.

A separate ReturnPro survey of 500 US GLP-1 users sharpens the picture:

• 71% are buying more apparel as their size shifts.
• 58% report increased spending on premium or higher-priced clothing.
• More than half expect clothing expenditure to rise further once their weight stabilises.

The acceleration matters as much as the magnitude. A consumer cohort that buys more units, moves up the price ladder and expects spend to keep climbing gives brands a fast-turning replenishment pattern rather than a predictable seasonal curve.

How is sizing confidence shifting online to store?

The same ReturnPro panel suggests uncertainty is pulling consumers back into fitting rooms. 69% said they feel less confident about online sizing as their bodies change, with in-store trial becoming more important again.

The trade-off is rising returns. ReturnPro found 65% of GLP-1 consumers buy several sizes of the same garment intending to send back what does not fit, and 43% reported increased apparel return frequency. Almost half had already returned clothing that became too large before it could be worn.

For sourcing and merchandising teams, the implication is operational. Returns processing, multi-size ordering and allocation across the size run will all require reweighting. Branded DTC platforms already optimised for single-unit drop-ship will see margin compression that multichannel retailers, with store-level fit advice to lean on, may absorb more cleanly.

What does this mean for fibre suppliers and factory orders?

The size mix is the first casualty. PwC warns that rapidly shifting demand makes historic size distributions a less reliable guide for how many units to order in each size. Buyers who anchored cut orders to last season's run will mis-size the current one.

Nilit, the Israel-based producer of Sensil Nylon 6.6 fibres, frames the development as part of a wider shift toward wearing experience. "Consumers are increasingly looking beyond appearance to qualities including comfort, hand feel, moisture management and thermal regulation," the company said. It points to its Sensil Breeze, Aquarius and Innergy ranges as products built around those attributes — a positioning that fits the brief that mid-weight, stretch-forward jerseys will carry more of the next two seasons' reorder weight.

Resale platforms add a second-hand supply tailwind. Consumers simultaneously dispose of wardrobes that no longer fit and buy replacements in smaller sizes, pumping inventory into the secondary market at a moment when demand for lower-size new garments is also climbing.

Will the GLP-1 cohort reshape sourcing priorities?

The full scale of the GLP-1 effect on fashion remains to be quantified, and weight-loss drugs are only one of many pressures on apparel sales. With millions of consumers in the US and UK moving through several clothing sizes, sizing, fit, returns, resale and inventory planning decisions across brands, factories and fibre suppliers are likely to require recalibration through the next two buying cycles.